The American Cancer Society’s Cancer Action Network (ACS CAN) has expressed concern over recent executive actions that may impact cancer research funding. The organization, led by President Lisa Lacasse, emphasizes the importance of bipartisan support for cancer research.
While the federal government is the largest public funder of cancer research through the National Institutes of Health and National Cancer Institute, robust and sustained funding is crucial to preserve progress made in reducing cancer mortality. According to ACS CAN, cancer mortality has decreased by 34% since 1991 due to groundbreaking innovations in prevention, early detection, and treatment.
However, areas of concern persist, including rising cancer incidence in women and younger adults. ACS CAN urges the need for immediate action to investigate causes of these changes and identify solutions to ensure everyone has access to lifesaving treatments.
The organization will closely monitor the impact of executive actions on cancer research, innovation, and clinical trial access. With millions of people relying on innovative treatments, delays can have severe health consequences for patients, emphasizing the urgency for swift action.
Source: https://www.cancerhealth.com/article/updated-executive-actions-cause-confusion-concern-potential-impact-cancer-research